+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Oncolytic Virus Therapy Market Outlook to 2035

  • PDF Icon

    Report

  • 144 Pages
  • April 2023
  • Region: Global
  • Research Nester Pvt. Ltd
  • ID: 5786635
The global oncolytic virus therapy market is anticipated to grow with a CAGR of 27.07 % over the forecast period, i.e., 2023 - 2035. Factors such as the increasing prevalence of cancer cases worldwide, followed by the increasing healthcare expenditure and rising investment in cancer research & development are projected to drive the growth of the market in the coming years. Additionally, the increase in clinical trial and approval of new virus therapies are also expected to boost the market growth. The market is estimated to garner a revenue of about USD 1,150 million by the end of 2035, up from a revenue of about USD 85 million in the year 2022.

The global oncolytic virus therapy market is segmented into numerous segments, which include segmentation by therapy type, virus type, indication, demography, end-user, and by region. By therapy type, the market is segmented into HSV-based, adenovirus-based, reovirus, poxviruses, NDV (Newcastle disease virus), and others. By the end of 2035, the HSV-based oncolytic virus therapy segment is anticipated to garner the largest revenue of close to USD 375 Million. HSV helps in expressing immune evasion genes for instance ICP34.5, ICPo, US3, which are focused in inducing and activating host responses to evade the immune system and establish effective long-term latent infection. However, after various research in immunotherapy, it has been observed that treatment of melanoma via herpes simplex virus can address the challenge of the host’s innate antiviral defense mechanism by redirecting these immune cells to attack tumor cells instead via arming the HSV-based oncolytic virus. This has resulted in HSV type-1 in gaining maximum attention owing to the growth of the market’s segment.

On the basis of region, the global oncolytic virus therapy market is segmented into North America, Europe, Asia Pacific, and Rest of the World. The market in North America, amongst the market in all the other regions, is anticipated to garner the largest revenue of nearly USD 535 Million by the end of 2035. Moreover, in the year 2022, the market in the region generated a revenue of over USD 30 Million. An increasing demand for targeted therapies among the people, and the rising cancer cases in the country are anticipated to create a surge in demand for oncolytic virus therapies in the forthcoming years. Further, the country's improved research infrastructure and increasing investment in R&D in the healthcare industry alongside the government's initiatives are also some of the essential driving factors for market development over the forecast period.

Some of the prominent industry leaders in the global oncolytic virus therapy market that are included in our report are Amgen Inc., Shanghai Sunway Biotech Co., Ltd., Oncolys BioPharma Inc., TILT Biotherapeutics Ltd., Oncorus, Inc., Takara Bio Inc., Vyriad, Transgene sa, Lokon Pharma AB, Pfizer Inc., Rigvir Group, Shenzhen Sibiono GeneTech, Oncolytics Biotech Inc, Daiichi Sankyo, Kissei Pharmaceutical Co., Ltd., Boehringer Ingelheim, and others.

Table of Contents

1. An Outline of the Oncolytic Virus Therapy Market
1.1. Market Definition
1.2. Market Segmentation
1.3. Product Overview
2. Assumptions and Acronyms
3. Research Methodology
3.1. Research Process
3.2. Primary Research
3.2.1. Manufacturers
3.2.2. End-Users
3.3. Secondary Research
3.4. Market Size Estimation
4. Summary of the Report for Key Decision Marker
5. Forces of the Market Constituents
5.1. Factors/Drivers Impacting the Growth of the Market
5.2. Market Trends for Better Business Practices
6. Key Market Opportunities for Business Growth
6.1. Based on the Therapy Type
6.2. Based on the Virus Therapy
6.3. Based on the Indication
6.4. Based on Demography
6.5. Based on the End-User
6.6. Based on Geographical Presence
7. Major Roadblocks for the Market Growth
8. Government Regulation: How They Would Aid Business?
8.1. FDA
8.2. Others
9. Industry Risk Analysis
10. Global Economic Outlook: Challenges for Global Recovery and Market
10.1. Ukraine-Russia Crisis
10.2. Potential US Economic Slowdown
11. Impact of COVID-19 on Global Oncolytic Virus Therapy Market
11.1. Impact on Oncolytic Virus Therapy Manufacturers
11.2. Impact on End Users
11.3. Impact on Demand
12. Pipeline Analysis
13. Oncolytic Virus Platforms Under Evaluation
13.1. Adenovirus
13.2. Herpes Simplex Virus
13.3. Maraba Virus
13.4. Measles
13.5. Newcastle Disease Virus
13.6. Other
14. Epidemiology Analysis15. Analysis on the Oncolytic Virus Therapy
16. Competitive Landscape
16.1. Market Share Analysis, 2022
16.2. Competitive Positioning
16.2.1. Business Profiles of Key Enterprises
16.2.1.1. Detailed Overview
16.2.1.2. Assessment of Key Offering
16.2.1.3. Analysis of Growth Strategies
16.2.1.4. Exhaustive Analysis on Key Financial Indicators
16.2.1.5. Recent Developments and Strategies
16.2.2. Amgen Inc.
16.2.3. Shanghai Sunway Biotech Co., Ltd.
16.2.4. Oncolys BioPharma Inc.
16.2.5. TILT Biotherapeutics Ltd.
16.2.6. Oncorus, Inc.
16.2.7. Takara Bio Inc.
16.2.8. Vyriad
16.2.9. Transgene sa
16.2.10. Lokon Pharma AB
16.2.11. Pfizer Inc.
16.2.12. Rigvir Group
16.2.13. Shenzhen Sibiono GeneTech
16.2.14. Oncolytics Biotech Inc.
16.2.15. Daiichi Sankyo
16.2.16. Kissei Pharmaceutical Co., Ltd.
16.2.17. Boehringer Ingelheim
17. Global Oncolytic Virus Therapy Market Outlook & Projections, Opportunity Assessment, 2022 to 2035
17.1. Market Overview
17.2. Market Revenue by Value (USD Million) and Compound Annual Growth Rate (CAGR)
17.3. Year-on-Year (Y-o-Y) Growth Trend Analysis
17.3.1. By Therapy Type
17.3.1.1. HSV-based oncolytic virus therapy, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.1.2. Adenovirus-based oncolytic virus therapy, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.1.3. Reovirus, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.1.4. Poxviruses, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.1.5. NDV (Newcastle disease virus), Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.1.6. Others, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.2. By Virus Type
17.3.2.1. Oncolytic wild type viruses, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.2.2. Genetically engineered oncolytic viruses, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.3. By Indication
17.3.3.1. Head & neck cancer, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.3.2. Lung cancer, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.3.3. Kidney cancer, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.3.4. Liver cancer, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.3.5. Pancreatic cancer, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.3.6. Breast cancer, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.3.7. Colorectal cancer, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.3.8. Sarcoma, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.3.8.1. Bone cancer, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.3.8.2. Angiosarcoma, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.3.8.3. Fibrosarcoma, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.3.8.4. Leiomyosarcoma, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.3.8.5. Others, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.3.8.6. Melanoma, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.3.8.7. Others, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.4. By Demography
17.3.4.1. Adults, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.4.2. Pediatric, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.5. By End-User
17.3.5.1. Hospitals, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.5.2. Specialty clinics, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.5.3. Cancer research institutes, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.6. By Region
17.3.6.1. North America, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.6.2. Asia Pacific, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.6.3. Europe, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
17.3.6.4. Rest of World, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18. North America Oncolytic Virus Therapy Market Outlook & Projections, Opportunity Assessment, 2022 to 2035
18.1. Market Overview
18.2. Market Revenue by Value (USD Million) and Compound Annual Growth Rate (CAGR)
18.3. Year-on-Year (Y-o-Y) Growth Trend Analysis
18.3.1. By Therapy Type
18.3.1.1. HSV-based oncolytic virus therapy, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.1.2. Adenovirus-based oncolytic virus therapy, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.1.3. Reovirus, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.1.4. Poxviruses, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.1.5. NDV (Newcastle disease virus), Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.1.6. Others, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.2. By Virus Type
18.3.2.1. Oncolytic wild type viruses, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.2.2. Genetically engineered oncolytic viruses, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.3. By Indication
18.3.3.1. Head & neck cancer, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.3.2. Lung cancer, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.3.3. Kidney cancer, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.3.4. Liver cancer, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.3.5. Pancreatic cancer, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.3.6. Breast cancer, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.3.7. Colorectal cancer, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.3.8. Sarcoma, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.3.8.1. Bone cancer, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.3.8.2. Angiosarcoma, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.3.8.3. Fibrosarcoma, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.3.8.4. Leiomyosarcoma, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.3.8.5. Others, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.3.8.6. Melanoma, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.3.8.7. Others, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.4. By Demography
18.3.4.1. Adults, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.4.2. Pediatric, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.5. By End-User
18.3.5.1. Hospitals, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.5.2. Specialty clinics, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.5.3. Cancer research institutes, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.6. By Country
18.3.6.1. United States, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
18.3.6.2. Canada, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
19. Asia Pacific Oncolytic Virus Therapy Market Outlook & Projections, Opportunity Assessment, 2022 to 2035
19.1. Market Overview
19.2. Market Revenue by Value (USD Million) and Compound Annual Growth Rate (CAGR)
19.3. Year-on-Year (Y-o-Y) Growth Trend Analysis
19.3.1. By Therapy Type
19.3.2. By Virus Type
19.3.3. By Indication
19.3.4. By Demography
19.3.5. By End-User
19.3.6. By Region
19.3.6.1. China, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
19.3.6.2. Japan, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
19.3.6.3. Australia, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
19.3.6.4. Rest of Asia Pacific, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
20. Europe Oncolytic Virus Therapy Market Outlook & Projections, Opportunity Assessment, 2022 to 2035
20.1. Market Overview
20.2. Market Revenue by Value (USD Million) and Compound Annual Growth Rate (CAGR)
20.3. Year-on-Year (Y-o-Y) Growth Trend Analysis
20.3.1. By Therapy Type
20.3.2. By Virus Type
20.3.3. By Indication
20.3.4. By Demography
20.3.5. By End-User
20.3.6. By Region
20.3.6.1. Germany, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
20.3.6.2. United Kingdom, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
20.3.6.3. France, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
20.3.6.4. Italy, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
20.3.6.5. Spain, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
20.3.6.6. Rest of Europe, Market Value (USD Million), CAGR & Y-o-Y Growth Trend, 2022-2035F
21. Rest of World Oncolytic Virus Therapy Market Outlook & Projections, Opportunity Assessment, 2022 to 2035
21.1. Market Overview
21.2. Market Revenue by Value (USD Million) and Compound Annual Growth Rate (CAGR)
21.3. Year-on-Year (Y-o-Y) Growth Trend Analysis
21.3.1. By Therapy Type
21.3.2. By Virus Type
21.3.3. By Indication
21.3.4. By Demography
21.3.5. By End-User

Companies Mentioned

  • Amgen Inc.
  • Shanghai Sunway Biotech Co. Ltd.
  • Oncolys BioPharma Inc.
  • TILT Biotherapeutics Ltd.
  • Oncorus Inc.
  • Takara Bio Inc.
  • Vyriad
  • Transgene sa
  • Lokon Pharma AB
  • Pfizer Inc.
  • Rigvir Group
  • Shenzhen Sibiono GeneTech
  • Oncolytics Biotech Inc
  • Daiichi Sankyo
  • Kissei Pharmaceutical Co. Ltd.
  • Boehringer Ingelheim